On May 16, 2024 OneChain Immunotherapeutics S.L. (OneChain) and NanoCell Therapeutics Inc. (NanoCell), reported a strategic collaboration to develop a novel in vivo CAR-T therapy targeting B-cell lymphomas (Press release, NanoCell Therapeutics, MAY 16, 2024, View Source [SID1234643397]). This partnership combines OneChain’s advanced CD22 CAR technology with NanoCell’s innovative in vivo CAR-T technology platform, opening a new course for treatment in this disease area with persisting unmet need.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
NanoCell’s non-viral, DNA-based CAR-T technology platform has demonstrated compelling results in pre-clinical proof of concept studies, durable CAR-T expression and robust tumor control. This new approach offers a viable alternative to conventional viral methods, potentially establishing a new standard in the field.
OneChain’s proprietary CD22 CAR molecule was developed and optimized by Professor Pablo Menendez, founder of OneChain and Professor at the Josep Carreras Institute for Leukemia. Preclinical validation of this CD22 CAR has been published in multiple peer-reviewed academic journals1.
"Partnering with NanoCell allows us to integrate our CD22 CAR with their innovative in vivo CAR-T technology, aiming to enhance treatment options for B-cell lymphoma", said Stefanos Theoharis, CEO of OneChain Immunotherapeutics.
"We look forward to collaborating with OneChain Immunotherapeutics, and potentially offering innovative treatments beyond traditional CD19 therapies for patients with B-cell malignancies", added Maurts Geerlings, CEO of NanoCell Therapeutics.
To learn more about our work and stay updated about our latest developments, please visit our websites at View Source and View Source